Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitors

Background Inhibitors of sodium-glucose co-transporter-2 (SGLT2i) were found to improve renal outcome in diabetic patients in large prospective randomized trials. Yet, SGLT2i may acutely reduce kidney function through volume depletion, altered glomerular hemodynamics or intensified medullary hypoxia...

Full description

Bibliographic Details
Main Authors: Said Darawshi, Hiba Yaseen, Yuri Gorelik, Caroline Faor, Auryan Szalat, Zaid Abassi, Samuel N. Heyman, Mogher Khamaisi
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:Renal Failure
Subjects:
Online Access:http://dx.doi.org/10.1080/0886022X.2020.1801466
id doaj-5e8910168bb446eab64e6aeea97cdee1
record_format Article
spelling doaj-5e8910168bb446eab64e6aeea97cdee12021-03-18T14:42:06ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492020-01-0142183684410.1080/0886022X.2020.18014661801466Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitorsSaid Darawshi0Hiba Yaseen1Yuri Gorelik2Caroline Faor3Auryan Szalat4Zaid Abassi5Samuel N. Heyman6Mogher Khamaisi7Department of Medicine D, Ruth & Bruce Rappaport Faculty of Medicine, Rambam Health Care Campus, Technion-IITClinical Research Institute, Rambam Health Care CampusDepartment of Medicine D, Ruth & Bruce Rappaport Faculty of Medicine, Rambam Health Care Campus, Technion-IITDepartment of Medicine D, Ruth & Bruce Rappaport Faculty of Medicine, Rambam Health Care Campus, Technion-IITDepartment of Medicine, Hadassah Hebrew University HospitalDepartment of Physiology, Ruth & Bruce Rappaport Faculty of Medicine, Technion-IITDepartment of Medicine, Hadassah Hebrew University HospitalDepartment of Medicine D, Ruth & Bruce Rappaport Faculty of Medicine, Rambam Health Care Campus, Technion-IITBackground Inhibitors of sodium-glucose co-transporter-2 (SGLT2i) were found to improve renal outcome in diabetic patients in large prospective randomized trials. Yet, SGLT2i may acutely reduce kidney function through volume depletion, altered glomerular hemodynamics or intensified medullary hypoxia leading to acute tubular injury (ATI). The aim or this study was to prospectively assess the pathophysiology of acute kidney injury (AKI) in patients hospitalized while on SGLT2i, differing ATI from pre-renal causes using renal biomarkers. Methods Serum and urine Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Ischemia Molecule (KIM)-1, markers of distal and proximal tubular injury, respectively, were determined in 46 diabetic patients who were on SGLT2i upon hospitalization with an acute illness. Results Serum and urine NGAL, but not KIM-1, were significantly increased in 21 of the patients who presented with AKI upon admission, as compared with 25 patients that maintained kidney function. Both serum and urinary NGAL correlated with the degree of impaired renal function, which in many cases was likely the result of additional acute renal perturbations, such as sepsis. Conclusions Increased urinary and serum NGAL indicates that ATI, principally affecting distal tubular segments, may develop in some of the patients hospitalized with an acute illness and AKI while on SGLT2i. It is suggested that intensified medullary hypoxia by SGLT2i might be detrimental in this injury. By contrast, concomitantly unaltered KIM-1 might reflect improved cortical oxygenation by SGLT2i, and may explain an overall reduced risk of AKI with SGLT1i in large series. The independent potential of SGLT2i to inflict medullary hypoxic damage should be explored further.http://dx.doi.org/10.1080/0886022X.2020.1801466acute kidney failuresglt2 inhibitorshypoxiabiomarkerngalkim-1
collection DOAJ
language English
format Article
sources DOAJ
author Said Darawshi
Hiba Yaseen
Yuri Gorelik
Caroline Faor
Auryan Szalat
Zaid Abassi
Samuel N. Heyman
Mogher Khamaisi
spellingShingle Said Darawshi
Hiba Yaseen
Yuri Gorelik
Caroline Faor
Auryan Szalat
Zaid Abassi
Samuel N. Heyman
Mogher Khamaisi
Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitors
Renal Failure
acute kidney failure
sglt2 inhibitors
hypoxia
biomarker
ngal
kim-1
author_facet Said Darawshi
Hiba Yaseen
Yuri Gorelik
Caroline Faor
Auryan Szalat
Zaid Abassi
Samuel N. Heyman
Mogher Khamaisi
author_sort Said Darawshi
title Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitors
title_short Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitors
title_full Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitors
title_fullStr Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitors
title_full_unstemmed Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitors
title_sort biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (aki) while on sglt2 inhibitors
publisher Taylor & Francis Group
series Renal Failure
issn 0886-022X
1525-6049
publishDate 2020-01-01
description Background Inhibitors of sodium-glucose co-transporter-2 (SGLT2i) were found to improve renal outcome in diabetic patients in large prospective randomized trials. Yet, SGLT2i may acutely reduce kidney function through volume depletion, altered glomerular hemodynamics or intensified medullary hypoxia leading to acute tubular injury (ATI). The aim or this study was to prospectively assess the pathophysiology of acute kidney injury (AKI) in patients hospitalized while on SGLT2i, differing ATI from pre-renal causes using renal biomarkers. Methods Serum and urine Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Ischemia Molecule (KIM)-1, markers of distal and proximal tubular injury, respectively, were determined in 46 diabetic patients who were on SGLT2i upon hospitalization with an acute illness. Results Serum and urine NGAL, but not KIM-1, were significantly increased in 21 of the patients who presented with AKI upon admission, as compared with 25 patients that maintained kidney function. Both serum and urinary NGAL correlated with the degree of impaired renal function, which in many cases was likely the result of additional acute renal perturbations, such as sepsis. Conclusions Increased urinary and serum NGAL indicates that ATI, principally affecting distal tubular segments, may develop in some of the patients hospitalized with an acute illness and AKI while on SGLT2i. It is suggested that intensified medullary hypoxia by SGLT2i might be detrimental in this injury. By contrast, concomitantly unaltered KIM-1 might reflect improved cortical oxygenation by SGLT2i, and may explain an overall reduced risk of AKI with SGLT1i in large series. The independent potential of SGLT2i to inflict medullary hypoxic damage should be explored further.
topic acute kidney failure
sglt2 inhibitors
hypoxia
biomarker
ngal
kim-1
url http://dx.doi.org/10.1080/0886022X.2020.1801466
work_keys_str_mv AT saiddarawshi biomarkerevidencefordistaltubulardamagebutcorticalsparinginhospitalizeddiabeticpatientswithacutekidneyinjuryakiwhileonsglt2inhibitors
AT hibayaseen biomarkerevidencefordistaltubulardamagebutcorticalsparinginhospitalizeddiabeticpatientswithacutekidneyinjuryakiwhileonsglt2inhibitors
AT yurigorelik biomarkerevidencefordistaltubulardamagebutcorticalsparinginhospitalizeddiabeticpatientswithacutekidneyinjuryakiwhileonsglt2inhibitors
AT carolinefaor biomarkerevidencefordistaltubulardamagebutcorticalsparinginhospitalizeddiabeticpatientswithacutekidneyinjuryakiwhileonsglt2inhibitors
AT auryanszalat biomarkerevidencefordistaltubulardamagebutcorticalsparinginhospitalizeddiabeticpatientswithacutekidneyinjuryakiwhileonsglt2inhibitors
AT zaidabassi biomarkerevidencefordistaltubulardamagebutcorticalsparinginhospitalizeddiabeticpatientswithacutekidneyinjuryakiwhileonsglt2inhibitors
AT samuelnheyman biomarkerevidencefordistaltubulardamagebutcorticalsparinginhospitalizeddiabeticpatientswithacutekidneyinjuryakiwhileonsglt2inhibitors
AT mogherkhamaisi biomarkerevidencefordistaltubulardamagebutcorticalsparinginhospitalizeddiabeticpatientswithacutekidneyinjuryakiwhileonsglt2inhibitors
_version_ 1724215893159837696